National Institute of Pharmaceutical R&D Co. Ltd. has synthesized high affinity nerve growth factor receptor (NTRK1; TRKA) and its mutant inhibitors reported to be useful for the treatment of cancer.
Ajinomoto Co. Inc.'s Ajinomoto Bio-Pharma Services has announced a license agreement with Exelixis Inc. to incorporate AJICAP, Ajinomoto's proprietary site-specific bioconjugation and linker technologies, in the development of certain of Exelixis' antibody-drug conjugate (ADC) programs for cancer.
A Harvard Medical School research team developed a bifunctional therapeutic vaccine strategy by transforming living tumor cells into a potent agent with direct tumor killing and immunostimulatory abilities.
Medshine Discovery Inc. has identified proteolysis targeting chimeras (PROTACs) comprising cereblon (CRBN) ligands coupled to an androgen receptor targeting moiety via a linker acting as androgen receptor degradation inducers reported to be useful for the treatment of cancer.
Minghui Pharmaceutical (Hangzhou) Ltd. and Minghui Pharmaceutical (Shanghai) Ltd. have synthesized antibody-drug conjugates consisting of an antibody covalently linked to exatecan derivatives through a linker.
The advent of bispecific antibodies bridging two different cell types has enabled a new level of cell specificity in cancer biology that has only recently begun to be realized in the clinic.
Researchers at GM Biosciences Inc. have reported developed a novel CD38xCD3 bispecific IgM T-cell engager IGM-2644 with 10 binding sites for human CD38 (Kd=0.27nM; measured by biolayer interferometry) and one anti-CD3 site (Kd=2.1nM) designed to reduce safety concerns.
Ammax Bio Inc. has entered into an exclusive option with Evopoint Biosciences Co. Ltd. for a worldwide license, excluding Greater China, for the development and commercialization of a novel antibody-drug conjugate (ADC) for treating solid tumors.
Kronos Bio Inc. has entered into a discovery collaboration in the field of oncology with Genentech Inc., a member of the Roche Group, focused on discovering and developing small-molecule drugs that modulate transcription factor targets selected by Genentech.
RSS
